Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

CXCR4/SDF-1α-mediated chemotaxis in an in vivo model of metastatic esophageal carcinoma.

Gros SJ, Graeff H, Drenckhan A, Kurschat N, Blessmann M, Rawnaq T, Izbicki JR.

In Vivo. 2012 Jul-Aug;26(4):711-8.

PMID:
22773586
2.

Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, Graeff H, Schwaiger M, Kuhn W.

J Clin Oncol. 2005 Oct 20;23(30):7445-53. Epub 2005 Sep 12. Erratum in: J Clin Oncol. 2005 Dec 20;23(36):9445.

PMID:
16157939
3.

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.

Kuhn W, Rutke S, Späthe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H.

Cancer. 2001 Nov 15;92(10):2585-91.

PMID:
11745193
4.

High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.

Lutz V, Reuning U, Krüger A, Luther T, von Steinburg SP, Graeff H, Schmitt M, Wilhelm OG, Magdolen V.

Biol Chem. 2001 May;382(5):789-98.

PMID:
11517932
5.

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group.

J Natl Cancer Inst. 2001 Jun 20;93(12):913-20.

PMID:
11416112
6.

beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.

Hapke S, Gawaz M, Dehne K, Köhler J, Marshall JF, Graeff H, Schmitt M, Reuning U, Lengyel E.

Mol Cell Biol. 2001 Mar;21(6):2118-32.

7.

Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential.

Mueller J, Brebeck B, Schmalfeldt B, Kuhn W, Graeff H, Höfler H.

Virchows Arch. 2000 Dec;437(6):618-24.

PMID:
11193473
8.

RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene.

Muehlenweg B, Schnelzer A, Türkmen B, Lengyel E, Reuning U, Graeff H, Schmitt M, Magdolen V.

Methods Mol Med. 2001;39:299-306. doi: 10.1385/1-59259-071-3:299.

PMID:
21340784
9.

Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.

Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M.

J Clin Oncol. 2000 Oct 15;18(20):3495-502.

PMID:
11032590
10.

Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b.

Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E.

Oncogene. 2000 Jun 15;19(26):3013-20.

11.

Detection of micrometastases in sentinel lymph nodes of the breast applying monoclonal antibodies AE1/AE3 to pancytokeratins.

Kowolik JH, Kuhn W, Nährig J, Werner M, Obst T, Avril N, Schmitt M, Graeff H.

Oncol Rep. 2000 Jul-Aug;7(4):745-9.

PMID:
10854537
12.

Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator.

Magdolen V, Arroyo de Prada N, Sperl S, Muehlenweg B, Luther T, Wilhelm OG, Magdolen U, Graeff H, Reuning U, Schmitt M.

Adv Exp Med Biol. 2000;477:331-41. Review. No abstract available.

PMID:
10849761
13.

Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.

Hildenbrand R, Leitz M, Magdolen V, Luther T, Albrecht S, Graeff H, Stutte HJ, Bleyl U, Schmitt M.

Histopathology. 2000 Jun;36(6):499-504.

PMID:
10849091
14.

Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).

Krüger A, Soeltl R, Lutz V, Wilhelm OG, Magdolen V, Rojo EE, Hantzopoulos PA, Graeff H, Gänsbacher B, Schmitt M.

Cancer Gene Ther. 2000 Feb;7(2):292-9.

15.

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.

Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, Werner M, Dose J, Jänicke F, Graeff H, Schwaiger M.

J Clin Oncol. 2000 Apr;18(8):1689-95.

PMID:
10764429
16.

Neural network analysis of follow-up data in primary breast cancer.

Harbeck N, Kates R, Ulm K, Graeff H, Schmitt M.

Int J Biol Markers. 2000 Jan-Mar;15(1):116-22.

PMID:
10763154
17.

A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications.

Noack F, Schmitt M, Bauer J, Helmecke D, Krüger W, Thorban S, Sandherr M, Kuhn W, Graeff H, Harbeck N.

Int J Biol Markers. 2000 Jan-Mar;15(1):100-4. Review.

PMID:
10763150
18.

Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.

Harbeck N, Alt U, Berger U, Kates R, Krüger A, Thomssen C, Jänicke F, Graeff H, Schmitt M.

Int J Biol Markers. 2000 Jan-Mar;15(1):79-83.

PMID:
10763146
19.

Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.

Prechtl A, Harbeck N, Thomssen C, Meisner C, Braun M, Untch M, Wieland M, Lisboa B, Cufer T, Graeff H, Selbmann K, Schmitt M, Jänicke F.

Int J Biol Markers. 2000 Jan-Mar;15(1):73-8.

PMID:
10763145
20.

CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy.

Noack F, Helmecke D, Rosenberg R, Thorban S, Nekarda H, Fink U, Lewald J, Stich M, Schutze K, Harbeck N, Magdolen V, Graeff H, Schmitt M.

Int J Oncol. 1999 Oct;15(4):617-23.

PMID:
10493940
21.

Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.

Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M.

Breast Cancer Res Treat. 1999 Mar;54(2):147-57.

PMID:
10424405
22.

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.

Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, Höfler H, Jänicke F, Graeff H, Schmitt M.

Br J Cancer. 1999 May;80(3-4):419-26.

23.

Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression.

Wilhelm OG, Wilhelm S, Escott GM, Lutz V, Magdolen V, Schmitt M, Rifkin DB, Wilson EL, Graeff H, Brunner G.

J Cell Physiol. 1999 Aug;180(2):225-35.

PMID:
10395292
24.

Thrombophilic state in breast cancer.

Schmitt M, Kuhn W, Harbeck N, Graeff H.

Semin Thromb Hemost. 1999;25(2):157-66. Review.

PMID:
10357083
25.

Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.

Ried S, Jäger C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel E.

J Biol Chem. 1999 Jun 4;274(23):16377-86.

26.

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.

Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Späthe K, Dettmar P, Höfler H, Jänicke F, Schmitt M, Graeff H.

Br J Cancer. 1999 Apr;79(11-12):1746-51.

27.

HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.

Harbeck N, Ross JS, Yurdseven S, Dettmar P, Pölcher M, Kuhn W, Ulm K, Graeff H, Schmitt M.

Int J Oncol. 1999 Apr;14(4):663-71.

PMID:
10087312
28.
29.

Gender differences in myocardial blood flow dynamics: lipid profile and hemodynamic effects.

Duvernoy CS, Meyer C, Seifert-Klauss V, Dayanikli F, Matsunari I, Rattenhuber J, Höss C, Graeff H, Schwaiger M.

J Am Coll Cardiol. 1999 Feb;33(2):463-70.

30.

Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.

Reuning U, Guerrini L, Nishiguchi T, Page S, Seibold H, Magdolen V, Graeff H, Schmitt M.

Eur J Biochem. 1999 Jan;259(1-2):143-8.

31.

Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.

Fischer K, Lutz V, Wilhelm O, Schmitt M, Graeff H, Heiss P, Nishiguchi T, Harbeck N, Kessler H, Luther T, Magdolen V, Reuning U.

FEBS Lett. 1998 Oct 30;438(1-2):101-5.

32.

Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).

Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M.

Int J Oncol. 1998 Nov;13(5):893-906. Review.

PMID:
9772277
34.

FDG PET evaluation of granular cell tumor of the breast.

Hoess C, Freitag K, Kolben M, Allgayer B, Laemmer-Skarke I, Nathrath WB, Avril N, Roemer W, Schwaiger M, Graeff H.

J Nucl Med. 1998 Aug;39(8):1398-401.

35.

Prognostic impact of tumor biological factors on survival in node-negative breast cancer.

Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, Jänicke F, Höfler H, Graeff H, Schmitt M.

Anticancer Res. 1998 May-Jun;18(3C):2187-97.

PMID:
9703782
36.

Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.

Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Kuhn W, Graeff H, Schmitt M.

Anticancer Res. 1998 May-Jun;18(3C):2173-80.

PMID:
9703780
37.

Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.

Hildenbrand R, Glienke W, Magdolen V, Graeff H, Stutte HJ, Schmitt M.

Histochem Cell Biol. 1998 Jul;110(1):27-32.

PMID:
9681686
38.

Disease-adapted relapse therapy for ovarian cancer: results of a prospective study.

Kuhn W, Schmalfeldt B, Pache L, Späthe K, Ulm K, Renziehausen K, Nöschel H, Canzler E, Richter B, Kroner M, Tilch G, Janicke F, Graeff H.

Int J Oncol. 1998 Jul;13(1):57-63.

PMID:
9625803
39.

Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity.

Zhang Y, Weiler-Guettler H, Chen J, Wilhelm O, Deng Y, Qiu F, Nakagawa K, Klevesath M, Wilhelm S, Böhrer H, Nakagawa M, Graeff H, Martin E, Stern DM, Rosenberg RD, Ziegler R, Nawroth PP.

J Clin Invest. 1998 Apr 1;101(7):1301-9.

40.

Immunological and functional analyses of the extracellular domain of human tissue factor.

Magdolen V, Albrecht S, Kotzsch M, Haller C, Bürgle M, Jacob U, Grosser M, Kessler H, Graeff H, Müller M, Schmitt M, Luther T.

Biol Chem. 1998 Feb;379(2):157-65.

PMID:
9524067
41.

Optimized differential diagnosis of breast lesions by combined B-mode and color Doppler sonography.

Schelling M, Gnirs J, Braun M, Busch R, Maurer S, Kuhn W, Schneider KT, Graeff H.

Ultrasound Obstet Gynecol. 1997 Jul;10(1):48-53.

42.

Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.

Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F, Graeff H.

Thromb Haemost. 1997 Jul;78(1):285-96. Review.

PMID:
9198168
43.

Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.

Türkmen B, Schmitt M, Schmalfeldt B, Trommler P, Hell W, Creutzburg S, Graeff H, Magdolen V.

Electrophoresis. 1997 May;18(5):686-9.

PMID:
9194591
44.

Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.

Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, Graeff H, Müller M, Schmitt M.

Am J Pathol. 1997 Apr;150(4):1231-44.

45.

Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.

Bürgle M, Koppitz M, Riemer C, Kessler H, König B, Weidle UH, Kellermann J, Lottspeich F, Graeff H, Schmitt M, Goretzki L, Reuning U, Wilhelm O, Magdolen V.

Biol Chem. 1997 Mar-Apr;378(3-4):231-7.

PMID:
9165076
46.

Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.

Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F, Graeff H.

Br J Cancer. 1997;76(3):306-11.

47.

Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer.

Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Jänicke F, Nathrath W, Schmitt M, Graeff H, Höfler H.

Br J Cancer. 1997;75(10):1525-33.

48.

Angiogenin plasma levels during pregnancy.

Kolben M, Bläser J, Ulm K, Schmitt M, Schneider KT, Tschesche H, Graeff H.

Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):37-41.

PMID:
9024086
49.

Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

Avril N, Dose J, Jänicke F, Ziegler S, Römer W, Weber W, Herz M, Nathrath W, Graeff H, Schwaiger M.

J Natl Cancer Inst. 1996 Sep 4;88(17):1204-9.

PMID:
8780629
50.

[Postoperative thrombolytic therapy].

Kolben M, Höss C, Graeff H.

Internist (Berl). 1996 Jun;37(6):619-22. Review. German. No abstract available.

PMID:
8767995

Supplemental Content

Loading ...
Support Center